{"schema_version":"secwatch.filing_event.v1","accession":"0001759138-26-000033","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2026-06-11T11:01:13+00:00","discovered_at":"2026-06-11T11:05:00.248151+00:00","generated_at":"2026-06-11T11:07:21.237609+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Cabaletta Bio stockholders approve doubling authorized shares to 600M; re-elect directors","bullets":["Authorized common stock increased from 300M to 600M shares (80.4M for, 1.8M against).","Directors Scott Brun, M.D. and Shawn Tomasello, MBA re-elected as Class I directors to 3-year terms.","Ratified Ernst & Young LLP as independent auditor for FY 2026 (82.1M for).","Advisory say-on-pay passed with 27.5M for vs 26.0M against (broker non-votes 28.7M).","Proposal 3 (Plan Amendment) was withdrawn by Board before the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001759138-26-000033","json":"https://secwatch.observer/filing/0001759138-26-000033.json","markdown":"https://secwatch.observer/filing/0001759138-26-000033.md","text":"https://secwatch.observer/filing/0001759138-26-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000033/0001759138-26-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000033/caba-20260609.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:07:21.237609+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d83d84ea9426b7466a6922bbf2712e61870ab0f","claim":"Cabaletta Bio, Inc.: Increased authorized shares of common stock from 300,000,000 to 600,000,000 (effective 2026-06-09).","evidence_excerpt":"On June 9, 2026, the Company filed a Certificate of Amendment to the Company’s Third Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware and the Certificate of Amendment became effective on filing.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000033/0001759138-26-000033-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2026-06-09"}],"fact_type":"governance_change"},{"claim_id":"2e56a4417ca0dd463e4423239501e47cb18eada6","claim":"Cabaletta Bio, Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2026-06-09 meeting.","evidence_excerpt":"The Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive officers in Proposal 5.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000033/0001759138-26-000033-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"},{"claim_id":"466363514820243a4c49da10c3fa49807886ffb3","claim":"Cabaletta Bio, Inc. shareholders approved Election of two Class I directors, Scott Brun, M.D. and Shawn Tomasello, MBA at the 2026-06-09 meeting.","evidence_excerpt":"The Company’s stockholders approved the Class I director nominees, Scott Brun, M.D. and Shawn Tomasello, MBA, recommended for election in Proposal 1 at the Annual Meeting.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000033/0001759138-26-000033-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"},{"claim_id":"914f603f6005359d0e54fa0e8eab9b139302fea5","claim":"Cabaletta Bio, Inc. shareholders approved Adjournment proposal to permit further solicitation if needed for Charter Amendment Proposal at the 2026-06-09 meeting.","evidence_excerpt":"Although Proposal 6 was deemed not necessary because there was a quorum present and there were sufficient proxies at the time of the Annual Meeting to approve the Charter Amendment Proposal, it was approved by the requisite vote as follows","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000033/0001759138-26-000033-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"},{"claim_id":"b0bd40df1b5459c3afa6b6935e4387bd4abc68f5","claim":"Cabaletta Bio, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.","evidence_excerpt":"The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, recommended for ratification in Proposal 2 at the Annual Meeting.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000033/0001759138-26-000033-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"},{"claim_id":"cc6133c1c6755169ab02dd32c34b61ceae4732d6","claim":"Cabaletta Bio, Inc. shareholders approved Amendment to Third Amended and Restated Certificate of Incorporation to increase authorized shares of common stock from 300,000,000 to 600,000,000 at the 2026-06-09 meeting.","evidence_excerpt":"The Company’s stockholders approved the amendment to the Company's Third Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 600,000,000, recommended for approval as Proposal 4 at the Annual Meeting.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000033/0001759138-26-000033-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}